<SEC-DOCUMENT>0001558370-20-002291.txt : 20200310
<SEC-HEADER>0001558370-20-002291.hdr.sgml : 20200310
<ACCEPTANCE-DATETIME>20200310091700
ACCESSION NUMBER:		0001558370-20-002291
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20200310
FILED AS OF DATE:		20200310
DATE AS OF CHANGE:		20200310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		20700046

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6-k.htm
<DESCRIPTION>6-K
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 3/10/2020 7:16:50 AM-->
<html>
	<head>
		<title>
			gmab_Current_Folio_6K_10Mar20
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt solid #000000 ;border-bottom:1pt solid #000000 ;text-indent:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Washington,&nbsp;D.C. 20549</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<br><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">FORM&nbsp;6-K</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&nbsp;13a&#8209;16 OR&nbsp;15d&#8209;16</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">FOR THE&nbsp;MONTH OF&nbsp;MARCH 2020</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">COMMISSION FILE NUMBER 001-38976&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 18pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:18pt;">Genmab A/S<br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#333333;font-size:9.5pt;background-color: #FFFFFF;">(Exact name of Registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Kalvebod&nbsp;Brygge 43</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">1560 Copenhagen V</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Denmark</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">+45 70 20 27 28<br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#333333;font-size:9.5pt;background-color: #FFFFFF;">(Address of principal executive offices)</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1pt;color:black;background-color:black;" align="center"></div>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&nbsp;20&#8209;F or&nbsp;Form&nbsp;40&#8209;F.</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Form&nbsp;20&#8209;F&nbsp;</font><font style="display:inline;font-size:8pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form&nbsp;40&#8209;F&nbsp;</font><font style="display:inline;">&#x2610;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Indicate by check mark if the registrant is submitting the Form&nbsp;6&#8209;K in paper as permitted by Regulation&nbsp;S&#8209;T Rule&nbsp;101(b)(1)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Yes&nbsp;</font><font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;</font><font style="display:inline;font-size:8pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Indicate by check mark if the registrant is submitting the Form&nbsp;6&#8209;K in paper as permitted by Regulation&nbsp;S&#8209;T Rule&nbsp;101(b)(7)</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:0pt;text-align:center;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Yes&nbsp;</font><font style="display:inline;">&#x2610;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;</font><font style="display:inline;font-size:8pt;">&#x2612;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;background-color: #FFFFFF;">This report on Form&nbsp;6-K&nbsp;shall be deemed to be&nbsp;</font><font style="display:inline;">incorporated by reference</font><font style="display:inline;color:#000000;background-color: #FFFFFF;">&nbsp;in Genmab A/S&#x2019;s registration statements on&nbsp;Form&nbsp;S-8&nbsp;(File&nbsp;No.&nbsp;333-232693)&nbsp;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font>
		</p>
		<p style="margin:0pt;text-indent:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt solid #000000 ;border-bottom:3pt solid #000000 ;text-indent:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 1pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:1pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">SIGNATURE</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">
			<tr>
				<td valign="bottom" style="width:51.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">nthony</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td colspan="2" valign="bottom" style="width:49.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">GENMAB A/S</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">BY:</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">/s/ Anthony Pagano</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Name: Anthony Pagano</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:51.00%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.70%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:45.30%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Title: Executive Vice President &amp; Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">DATE: March 10, 2020</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">EXHIBIT&nbsp;INDEX</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;">
			<tr>
				<td valign="top" style="width:68.50pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size: 10pt;">
						<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">O</font></p>
				</td>
				<td valign="top" style="width:445.25pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:1pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Exhibit</font></p>
				</td>
				<td valign="top" style="width:445.25pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;text-decoration:underline;">Description of Exhibit</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:445.25pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:68.50pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">99.1</font></p>
				</td>
				<td valign="top" style="width:445.25pt;padding:0pt 6.5pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-family:Times New Roman,Times,serif;">Company Announcement Dated&nbsp;March 10, 2020</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Toppan Merrill Bridge  9.5.2.4-->
<!--Created on: 3/10/2020 7:16:49 AM-->
<html>
	<head>
		<title>
			gmab_Ex99_1_10Mar20
		</title>
	</head>
	<body><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Exhibit 99.1</font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-99d1g001.jpg" style="width: 2.103904in; height: 0.6249223in" alt="Picture 6"></font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 13pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;">Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer </font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:12pt;">Company Announcement</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Copenhagen, Denmark; March 10, 2020 &#x2013; Genmab A/S (Nasdaq: GMAB) announced today that Anthony Mancini will join the company as Executive Vice President and Chief Operating Officer, effective March 23, 2020. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Mr. Mancini will be responsible for overseeing Genmab&#x2019;s Commercial, Corporate Development, Business Development and Information Technology functions.&nbsp;He will join the Executive Management Team of Chief Executive Officer, Dr. Jan van de Winkel, Chief Development Officer, Dr. Judith Klimovsky, and Chief Financial Officer, Anthony Pagano. Mr. Mancini&#x2019;s responsibilities will include the successful direction, planning, and execution of all aspects of Genmab&#x2019;s commercial strategies and the further optimization of the organization to achieve its inspirational vision of transforming cancer treatment and bringing its own differentiated therapeutic products to the market. </font>
		</p>
		<p style="margin:6pt -23.75pt 3pt 0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Mr. Mancini brings to Genmab </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;">strategic and operational leadership as well as a consistent track record of growth across North America, Europe and Australia. Mr. Mancini has held positions of increasing responsibility in sales, marketing and general management; leading launches and alliances across various therapeutic areas including Oncology, Hematology, Cardiovascular, Immunology, Metabolic Disease, and Virology. Most recently, he led Bristol-Myers Squibb&#x2019;s US Innovative Medicines Unit, a team of over 1100 people focused on Immunology &amp; Cardiovascular diseases.</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> &nbsp; &nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&#x201C;I am delighted to welcome Anthony to the Executive Management Team in the newly created role of Chief Operating Officer, and look forward to his contributions in building our growing global operations during this transformational stage for Genmab,&#x201D; said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. &#x201C;Anthony shares our determination to bring truly differentiated new cancer treatments to the market that will deliver on our commitment to improve patients&#x2019; lives while fostering a culture of excellence and passion for innovation. On behalf of the Board of Directors and the full Global Leadership Team, I warmly welcome Anthony to Genmab.&#x201D;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:10pt;">Mr. Mancini will be based in Princeton, New Jersey, U.S., whilst traveling regularly to Genmab&#x2019;s other sites in Copenhagen, Denmark, Utrecht, The Netherlands, and Tokyo, Japan. </font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;color:#000000;font-size:10pt;">He holds a Bachelor of Science in Biochemistry from the University of Ottawa, Canada, an MBA from Clemson University, South Carolina, USA, and participated in the General Management Program, CEDEP at INSEAD, Fontainebleau, France.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">About Genmab </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company is the creator of three approved antibodies: DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (daratumumab, under agreement with Janssen Biotech, Inc.) for the treatment of certain multiple myeloma indications in territories including the U.S., Europe and Japan, Arzerra</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> (ofatumumab, under agreement with Novartis AG), for the treatment of certain chronic lymphocytic leukemia indications in the U.S., Japan and certain other territories and TEPEZZA&#x2122; (teprotumumab, under agreement with Roche granting sublicense to Horizon Therapeutics plc) for the treatment of thyroid eye disease in the U.S. Daratumumab is in clinical development by Janssen for the treatment of additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development by Novartis for the treatment of relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform for generation of bispecific antibodies, the HexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform, which creates effector function enhanced antibodies, the HexElect</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:5pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"> platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with sites in Utrecht,</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:12pt 0pt 0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

			&nbsp;

		</p>

		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">

			<tr>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Genmab A/S</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Tel: +45 7020 2728</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Company Announcement no. 11</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Kalvebod Brygge 43</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Fax: +45 7020 2729</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Page 1/2</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">21560 Copenhagen V, Denmark</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">www.genmab.com&nbsp;</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">CVR no. 2102 3884</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">LEI Code 529900MTJPDPE4MHJ122</font></p>

				</td>

			</tr>

		</table></div>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:always;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><div style="width:100%">

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;"><img src="ex-99d1g001.jpg" style="width: 2.103904in; height: 0.6249223in" alt="Picture 2"></font>

		</p>

		<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 13pt;">

			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;font-size:13pt;">Genmab Announces Appointment of Anthony Mancini to Newly Created Position of Chief Operating Officer </font>

		</p>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">the Netherlands, Princeton, New Jersey, U.S. and Tokyo, Japan.<br></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">Contact:<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><br></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Marisol Peron, Corporate Vice President, Communications &amp; Investor Relations </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">T: +1 609 524 0065; E: <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;">mmp@genmab.com</font></a></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-weight:bold;">For Investor Relations: </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">Andrew Carlsen, Senior Director, Investor Relations</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">T: +45 3377 9558; E: <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;">acn@genmab.com</font></a>&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<br><font style="display:inline;font-family:Arial,Helvetica,sans-serif;"></font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:8pt;">This Company Announcement contains forward looking statements. The words &#x201C;believe&#x201D;, &#x201C;expect&#x201D;, &#x201C;anticipate&#x201D;, &#x201C;intend&#x201D; and &#x201C;plan&#x201D; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#x2019;s most recent financial reports, which are available on <a href="#\o"><font style="font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:8pt;">www.genmab.com</font></a> and the risk factors included in Genmab&#x2019;s final prospectus for our U.S. public offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at <a href="#"><font style="font-family:Arial,Helvetica,sans-serif;font-style:italic;font-size:8pt;">www.sec.gov</font></a>. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. </font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<br><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">Genmab A/S and/or its subsidiaries own the following trademarks: Genmab</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; the Y-shaped Genmab logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; Genmab in combination with the Y-shaped Genmab logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; HuMax</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; DuoBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; DuoBody in combination with the DuoBody logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; HexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">HexaBody in combination with</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&nbsp;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">the HexaBody logo</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; DuoHexaBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; HexElect</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">; and UniBody</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">. Arzerra</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"> is a trademark of Novartis AG or its affiliates. DARZALEX</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;font-size:4pt;top:-4pt;position:relative;line-height:100%">&#xAE;</font><font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;"> is a trademark of Janssen Pharmaceutica NV. TEPEZZA&#x2122; is a trademark of Horizon Therapeutics plc.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 8pt;">
			<font style="display:inline;font-family:Arial,Helvetica,sans-serif;font-size:8pt;">&nbsp;</font>
		</p></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:12pt 0pt 0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

			&nbsp;

		</p>

		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;">

			<tr>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:33.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="width:34.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;">

					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">

						&nbsp;</p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Genmab A/S</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Tel: +45 7020 2728</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Company Announcement no. 11</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Kalvebod Brygge 43</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Fax: +45 7020 2729</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">Page 2/2</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">21560 Copenhagen V, Denmark</font></p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">www.genmab.com&nbsp;</font></p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">CVR no. 2102 3884</font></p>

				</td>

			</tr>

			<tr>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:33.00%;padding:0pt;">

					<p style="margin:0pt;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						&nbsp;</p>

				</td>

				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:34.00%;padding:0pt;">

					<p style="margin:0pt;text-align:right;font-family:Arial,Helvetica,sans-serif;font-size: 8pt;">

						<font style="display:inline;">LEI Code 529900MTJPDPE4MHJ122</font></p>

				</td>

			</tr>

		</table></div>

		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:5.88235294117647%;margin-right:5.88235294117647%;page-break-after:avoid;"><div style="background-color:#000000;clear:both;height:2pt;border:0;margin:30pt 0pt 30pt 0pt;"></div></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ -OQMXSU
MV'Q-=V5K=R6=O;.$1(P 6X!W$]\Y_*NB^'OC:\UNYDTO4V$EPL?F13A0"X&
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M+87ZR'[.Q>/8Y7DXZ_E6BJ+VB?D<SP\OJ\X=6[_B:]>9_#;_ )&KQ+_UT_\
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ESBZMHI);G'RRSMN*_3  'UQ72TJDDDH1Z%8:E*4G6J;R_!'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
